Dribble to Stop Diabetes unites NBA with American Diabetes Association, Sanofi-Aventis
NEW YORK — The National Basketball Association, the Women’s National Basketball Association and the NBA Development League are at the forefront of a new campaign that seeks to raise awareness about diabetes prevention.
Teaming up with the American Diabetes Association and drug maker Sanofi-Aventis, the NBA leagues will participate in the Dribble to Stop Diabetes campaign, which will kick off with a nationally broadcasted public service announcement that will premiere during the NBA All-Star Celebrity Game on ESPN. The announcement will feature campaign ambassadors Dwight Howard of the Orlando Magic, Alana Beard of the Washington Mystics and NBA legends Walt Frazier and Chris Dudley.
As part of the campaign, NBA, WNBA and NBA D-League teams will host Dribble to Stop Diabetes in-arena nights that will include on-court activation and PSAs. Additionally, teams also will provide fans with diabetes educational materials, and Dribble to Stop Diabetes clinics will take place during the 2011 WNBA Finals.
More information about Dribble to Stop Diabetes can be found on the campaign’s newly launched website.
Amicus’ Amigal improves symptoms among Fabry disease patients in trial
CRANBURY, N.J. — Amicus Therapeutics received good results from its mid-stage trial of a drug for a rare, genetic disorder, the drug maker said Wednesday.
Amicus announced results of a phase-2 extension study of the investigational drug Amigal (migalastat hydrochloride) designed to improve kidney function in patients with the enzyme disorder Fabry disease. The study — an extension of the original, three- to six-month phase-2 study — used two criteria to measure kidney function, protein in the urine during a 24-hour period and a commonly used measure called estimated glomerular filtration rate, or eGFR. Twenty-six patients participated in the original study, while 23 enrolled in the extension study.
The company said preliminary data indicated that eGFR was stable after three to four years of treatment with Amigal, while protein levels in the urine also were reduced among patients in the extension study.
The company plans to present study results at the Lysosomal Disease Network WORLD Symposium in Las Vegas this week.
Sanofi-Aventis obtains Genzyme for $20.1 billion
CAMBRIDGE, Mass. — French drug maker Sanofi-Aventis will acquire U.S. biotech giant Genzyme for $20.1 billion, under an agreement the two companies announced Wednesday.
Sanofi has had its eyes on Genzyme since last July, when it offered $18.5 billion, or $69 per share, for the Cambridge, Mass.-based company, but Genzyme initially dismissed Sanofi’s offer as too low. Under the new $74-per-share agreement, Genzyme shareholders will be eligible for additional milestone payments related to the multiple sclerosis treatment Lemtrada (alemtuzumab), or milestone payments related to 2011 production volumes for the Fabry disease drug Fabrazyme (agalsidase beta) and the Gaucher disease drug Cerezyme (imiglucerase).
Sanofi said it plans to make Genzyme its “global center for excellence” in rare diseases. Genzyme has long specialized in treatments for rare, inherited disorders, such as Fabry disease, Gaucher disease and Pompe disease.
Sanofi’s July announcement came not long after Genzyme agreed to pay $175 million to the federal government to address manufacturing problems the Food and Drug Administration found at one of its manufacturing plants in 2009. Those problems led to contamination of supplies of its drugs and nationwide shortages of Fabrazyme and Cerezyme.